

## CLAIMS

What is claimed is:

1. A method of treating inflammatory in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of COX2 inhibitors selected from the group consisting of (i) celecoxib (Celebrex<sup>R</sup>) [A], rofecoxib (Vioxx<sup>R</sup>) [B], and other specific COX2 inhibitors [C], (ii) low dose aspirin (70-85 mg), and (iii) antioxidant flavanoids, flavonoids or isoflavones.
2. The method of claim 1 wherein the combination of (i) and (ii) or (iii) provides improved efficacy or safety effect in tumor growth and metastasis in conjunction with chemotherapy, radiotherapy or tumor surgery.
3. The method of claim 1, wherein the combination administered is a combination of the COX2 inhibitors, flavanoids, and a low dose aspirin or other antiplatelet agents for the prevention and treatment of various thromboembolic disorders as defined earlier in the background.
4. The method of claim 1, wherein the combination administered is a combination of the COX2 inhibitors, flavanoids, and a low dose aspirin or other antiplatelet agents for the prevention and treatment of various inflammatory disorders as defined earlier in the background.
5. The method of claim 1-5, wherein the COX2 inhibitors is compound [A], compound [B] or compound [C] and low dose aspirin of 70-85 mg in an enteric coated formulation. This preferred enteric-coated formulation should allow for improved efficacy and safety.